Sign In
Buy GBS
$0.81
-0.111 (-12.05%)
At Close: Jan 27, 2023
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
03:00am, Wednesday, 27'th May 2026
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
11:00pm, Monday, 25'th May 2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Is Intuit (INTU) Undervalued After Q3 FY26 Earnings? EPS $11.09 Beats Estimates, Revenue $8.56B Misses; GF Score 87/100, 51.2% Undervalued
04:33pm, Wednesday, 20'th May 2026
Filing date: May 20, 2026GAAP diluted EPS was $11.09, which is higher than the estimated EPS of $10.65.Revenue was $8,558 million, which is below the estimated
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
03:00am, Tuesday, 19'th May 2026
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
10:00am, Monday, 11'th May 2026
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and
Larry Robbins Increases Stake in DXC Technology Co
08:38pm, Wednesday, 01'st Apr 2026
Transaction Overview On March 20, 2026, Larry Robbins (Trades, Portfolio), through Glenview Capital Management, increased the firm's stake in DXC Technology Co
Kimberly-Clark Appoints Francesco Tinto as Chief Information & GBS Officer
08:00am, Friday, 06'th Mar 2026
DALLAS, March 6, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Francesco Tinto as Chief Information & Global Business Services (GBS) Officer, effecti
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Car
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compa
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
LUND, Sweden , Dec. 17, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS
Fidelity Investments Featured Among Top 20 Global Business Services (GBS) Technology Employers in India
06:30am, Thursday, 06'th Oct 2022
Business Wire IndiaFidelity Investments India (FMR – Fidelity Management and Research) has announced that the company is listed among the top 20 global business services (GBS) technology employers i
TIAA Global Business Services India appoints Oindrila Majumdar as new CEO
12:30am, Thursday, 22'nd Sep 2022
Jayant Patwardhan to become Executive Chairman MUMBAI, India, Sept. 22, 2022 /PRNewswire/ — TIAA Global Business Services (GBS) India, the Global Capability Center of TIAA, a leading provider of sec
